Race to stop long COVID: major trial tests common drug
NCT ID NCT05852873
Summary
This large study is testing if taking the antiviral drug Paxlovid for a short time right after getting COVID-19 can prevent people from developing long-lasting symptoms, known as long COVID. About 2,000 adults in Norway with recent, confirmed COVID-19 will take either Paxlovid or a placebo pill for 5 days. Researchers will then track their health for months to see if the drug reduces problems like severe tiredness, shortness of breath, and brain fog.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Haukeland University Hospital
Bergen, Vestland, 5021, Norway
Conditions
Explore the condition pages connected to this study.